1. Eriodictyol is a flavonoid with anti-inflammatory and antioxidant activities, it may be a potent anti-inflammatory inhibitor of JNK.
2. Eriodictyol may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance.
3. Eriodictyol may be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness inAtopic dermatitis.
4. Eriodictyol attenuates the degree of retinal inflammation and plasma lipid peroxidation preserving the blood-retinal barrier (BRB) in early diabetic rats.
5. Eriodictyol acts as an antagonist of the transient potential vanilloid 1 receptor (TRPV1) receptor and as an antioxidant, it induces antinociception without some of the side effects and limitations such as hyperthermia that are expected for TRPV1 antagonists.
6. Eriodictyol upregulates HO-1 and γ-GCS expression through the activation of Nrf2/ARE pathway and protects PC12 cells against H2O2 -induced oxidative stress.
7. Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation.
8. Eriodictyol has vasodilator effect, the effect in rat thoracic aorta could be partially related to the inhibition of calcium influx or other enzymatic protein subsequent to activation of PKC related to the activation of contractile proteins like myosin light chain kinase (MLCK).
1. Lithospermic acid is a cardiotonic agent;
1. Lithospermic acid possesses anti-HIV activity.
2. Lithospermic acid shows anti-gonadotrophic and anti-thyroidal effects.
1. Astragalin may be a potential agent in the treatment of osteoarthritis.
2. Astragalin can be effective in allaying ROS-promoted bronchial fibrosis through inhibiting autophagosome formation in airways.
3. Astragalin ameliorates oxidative stress-associated epithelial eosinophilia and apoptosis through disturbing TLR4-PKCβ2-NADPH oxidase-responsive signaling.
4. Astragalin exerts anti-inflammatory properties possibly via the inactivation of TLR4-mediated NF-κB and mitogen-activated protein kinases signaling pathways in LPS-stimulated mMECs.
5. Astragalin exerts anti-inflammatory properties in LPS-mediated mastitis, possibly through inhibiting inhibition of the NF-κB signaling pathway, which mediates the expression of pro-inflammatory cytokines.
1. Isoquercitrin is a potential stimulator of bone mineralization used for prophylaxis of osteoporotic disorders.
2. Isoquercitrin may be as a potential therapeutic agent against neurodegeneration in Parkinson's disease.
3. Isoquercitrin is an inhibitor of Wnt/β-catenin and may be as a potential novel anti-tumoral agent, such as against human pancreati、 liver cancer related to opioid receptors and to the activation of the mitogen-activated protein kinase (MAPK) signalling pathway.
1. Crocin can relax smooth muscles, has a great potential to be a candidate for the treatment of asthma.
2. Crocin can protect liver and skeletal muscle tissue against exercise-induced oxidative damage by preventing reactive oxygen species (ROS) production.
3. Crocin improves toxic effects of DZN via reducing lipid peroxidation and restoring altered contractile and relaxant responses in rat aorta.
4. Crocin protects rat gastric mucosa against ethanol-induced injury via anti-inflammatory, anti-oxidative, anti-apoptotic and mucin-secretagogue mechanisms that are probably mediated by enhanced PGE2 release.
5. Crocin can significantly inhibit the growth of HO-8910 cells and arrest them in the G0/G1 phase. Crocin can also promote ovarian cancer HO-8910 cell apoptosis, most likely by increasing p53 and Fas/APO-1 expression, and then activating the apoptotic pathway regulated by Caspase-3.